Profile data is unavailable for this security.
About the company
Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
- Revenue in SEK (TTM)859.83m
- Net income in SEK193.34m
- Incorporated1997
- Employees270.00
- LocationSurgical Science Sweden ABDrakegatan 7 A, 3 tr.GOETEBORG 412 50SwedenSWE
- Phone+46 317416560
- Websitehttps://surgicalscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nordhealth As | 507.22m | -95.91m | 1.69bn | 403.00 | -- | 3.33 | 57.71 | 3.33 | -1.24 | -1.24 | 6.53 | 11.26 | 0.475 | -- | 9.49 | 1,288,007.00 | -8.98 | -- | -10.01 | -- | 85.89 | -- | -18.91 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
| Genovis AB | 129.73m | 27.91m | 1.81bn | 32.00 | 64.74 | 8.13 | 46.13 | 13.93 | 0.4263 | 0.4263 | 1.98 | 3.39 | 0.4239 | -- | -- | 3,506,189.00 | 9.12 | 18.56 | 9.80 | 21.45 | 64.69 | 65.51 | 21.51 | 23.88 | -- | -- | 0.2555 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Stille AB | 487.43m | 50.86m | 1.89bn | 151.00 | 33.19 | 2.81 | 25.16 | 3.87 | 6.33 | 6.33 | 60.94 | 74.85 | 0.6978 | 2.10 | 8.49 | 4,598,368.00 | 7.28 | 7.03 | 8.70 | 8.19 | 49.17 | 43.93 | 10.43 | 9.85 | 1.12 | 7.41 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
| Detection Technology Oyj | -1.16tn | -1.16tn | 2.36bn | 464.00 | -- | 2.75 | -- | -- | -- | -- | -- | 5.03 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.39 | -- | 0.00 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| BICO Group AB | 2.25bn | -786.80m | 2.37bn | 828.00 | -- | 0.8204 | -- | 1.05 | -11.15 | -15.20 | 31.92 | 41.79 | 0.3602 | 2.15 | 4.47 | 2,547,964.00 | -12.62 | -- | -14.44 | -- | 55.70 | -- | -35.03 | -- | 2.23 | -0.5705 | 0.397 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Medistim ASA | 545.42m | 101.33m | 2.54bn | 152.00 | 25.05 | 6.28 | 20.13 | 4.66 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| CellaVision AB | 737.16m | 150.21m | 5.04bn | 228.00 | 33.58 | 6.57 | 26.29 | 6.84 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| RaySearch Laboratories AB (publ) | 1.17bn | 175.06m | 5.17bn | 414.00 | 38.01 | 8.20 | 12.41 | 4.42 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| Surgical Science Sweden AB | 859.83m | 193.34m | 7.25bn | 270.00 | 37.48 | 1.63 | 28.79 | 8.43 | 3.79 | 3.79 | 16.85 | 87.19 | 0.1769 | 1.56 | 6.80 | 3,307,035.00 | 3.98 | 4.49 | 4.21 | 4.78 | 68.65 | 70.06 | 22.49 | 23.75 | 3.73 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Arjo AB (publ) | 11.18bn | 511.00m | 8.39bn | 6.85k | 17.60 | 1.14 | 5.61 | 0.7505 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Revenio Group Oyj | 1.19bn | 221.01m | 8.42bn | 230.00 | 37.67 | 7.13 | 29.86 | 7.09 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
Data as of Nov 21 2024. Currency figures normalised to Surgical Science Sweden AB's reporting currency: Swedish Krona SEK
36.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 3.27m | 6.41% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 3.13m | 6.13% |
| Fj�rde AP-fondenas of 31 May 2024 | 2.85m | 5.58% |
| Teknik Innovation Norden Fonder ABas of 31 May 2024 | 2.70m | 5.29% |
| Swedbank Robur Fonder ABas of 31 Oct 2024 | 1.84m | 3.60% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 2023 | 1.52m | 2.97% |
| Montanaro Asset Management Ltd.as of 31 May 2024 | 1.09m | 2.14% |
| Amundi Asset Management SA (Investment Management)as of 06 Nov 2024 | 1.06m | 2.07% |
| Carnegie Fonder ABas of 30 Sep 2024 | 1.02m | 2.01% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 31 Oct 2024 | 356.21k | 0.70% |
More ▼
Data from 31 Dec 2022 - 13 Nov 2024Source: FactSet Research Systems Inc.
